Pricing Log in Create free account
Saturday 17 October 2026 Export ZYME’s income statement to Excel — free account

Zymeworks Inc.

ZYME Healthcare Biotechnology

Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024. In the quarter to June 2026, revenue fell 90.6%, EPS fell 2,166.7% and free cash flow fell 385.5%, each against the same quarter a year earlier.

25.07 0.68 −2.64%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
16.2×
Dividend yield
—
F-score
7/9
Altman Z
11.56
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Zymeworks Inc. (ZYME) Business Profile

Updated before January 2025

Company Overview

Zymeworks Inc. (NASDAQ: ZYME) is a clinical-stage biotechnology company headquartered in Vancouver, British Columbia, Canada. Founded in 2003, Zymeworks specializes in the development of multifunctional biotherapeutics, particularly for the treatment of cancer and other serious diseases. The company was co-founded by Ali Tehrani, who served as its CEO until 2022. The current CEO is Kenneth Galbraith, who brings extensive experience in the biotechnology and pharmaceutical industries. Zymeworks operates with a mission to improve patient outcomes through innovative therapeutic solutions, leveraging its proprietary technology platforms and expertise in protein engineering.

Core Business Segments

Therapeutic Platforms

Zymeworks is renowned for its proprietary therapeutic platforms, which include:

  • Azymetric™ Platform: This platform enables the development of bispecific antibodies, which can simultaneously target two different antigens. This technology is pivotal in creating therapies that are more effective and have fewer side effects compared to traditional monoclonal antibodies.
  • EFECT™ Platform: This platform is designed to modulate immune cell activity, enhancing the efficacy of immunotherapies. It allows for precise control over immune responses, making it a valuable tool in cancer treatment.

Lead Product Candidates

Zymeworks’ pipeline includes several promising candidates:

  • ZW49: A bispecific antibody-drug conjugate (ADC) targeting HER2-expressing cancers. ZW49 is currently in clinical trials and has shown potential in treating breast, gastric, and other HER2-positive cancers.
  • ZW25 (zanidatamab): A bispecific antibody targeting HER2, designed to address unmet needs in HER2-expressing cancers. Zanidatamab has demonstrated encouraging results in clinical trials and is being developed in collaboration with global partners.

Partnerships and Collaborations

Zymeworks collaborates with leading pharmaceutical companies, including Merck, Eli Lilly, and BeiGene, to advance its therapeutic candidates and expand the reach of its platforms. These partnerships provide Zymeworks with additional resources and expertise to accelerate drug development.

Business Model

Zymeworks operates on a hybrid business model that combines in-house drug development with strategic partnerships. The company generates revenue through:

  • Licensing Agreements: Zymeworks licenses its Azymetric™ and EFECT™ platforms to pharmaceutical companies, earning upfront payments, milestone payments, and royalties on commercialized products.
  • Collaborative Research: The company engages in joint research and development projects with partners, sharing costs and expertise.
  • Product Sales: As its pipeline matures, Zymeworks aims to generate revenue from the commercialization of its therapeutic candidates.

This diversified approach allows Zymeworks to mitigate risks associated with drug development while maximizing the potential of its proprietary technologies.

Strategic Direction

Zymeworks is focused on achieving several strategic objectives:

  • Pipeline Expansion: The company is actively advancing its existing candidates through clinical trials while exploring new therapeutic areas, such as autoimmune diseases and infectious diseases.
  • Global Reach: Zymeworks aims to expand its presence in key markets, including North America, Europe, and Asia, through partnerships and direct commercialization efforts.
  • Sustainability Goals: The company is committed to minimizing its environmental footprint by adopting sustainable practices in its operations and supply chain.
  • Innovation: Zymeworks continues to invest in research and development to enhance its platforms and discover novel therapeutic approaches.

Competitive Landscape

Zymeworks operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Genentech (a subsidiary of Roche): A leader in antibody-based therapies, particularly in oncology.
  • Amgen: Known for its innovative biologics and biosimilars.
  • MacroGenics: Specializes in bispecific antibodies and immuno-oncology.
  • Seagen (formerly Seattle Genetics): Focused on ADCs for cancer treatment.

Despite the competition, Zymeworks differentiates itself through its proprietary platforms and focus on multifunctional biotherapeutics.

Risk Factors

Zymeworks faces several risks that could impact its business:

  • Clinical Trial Risks: The success of its pipeline depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Challenges: Obtaining regulatory approval for new therapies is a complex and time-consuming process.
  • Market Dependence: The company relies heavily on its lead candidates, ZW49 and zanidatamab, for future revenue.
  • Supply Chain Disruptions: Global supply chain issues could affect the availability of raw materials and manufacturing capabilities.
  • Competition: Intense competition in the biotechnology sector could limit market share and pricing power.

Recent Developments

  • Clinical Progress: Zymeworks recently announced positive interim results from its Phase 2 clinical trials for ZW49, demonstrating its potential as a best-in-class therapy for HER2-positive cancers.
  • Partnership Expansion: The company extended its collaboration with BeiGene to include additional therapeutic candidates, strengthening its presence in the Asian market.
  • Corporate Restructuring: Zymeworks implemented cost-saving measures and streamlined its operations to focus on core priorities, improving financial stability.
  • Global Trends: The COVID-19 pandemic highlighted the importance of biotechnology, leading to increased investment and interest in companies like Zymeworks.

Investment Considerations

Strengths

  • Innovative Platforms: Zymeworks’ proprietary technologies provide a competitive edge in the development of multifunctional biotherapeutics.
  • Strong Pipeline: The company has a robust pipeline with multiple candidates in advanced stages of development.
  • Strategic Partnerships: Collaborations with industry leaders enhance Zymeworks’ capabilities and market reach.
  • Experienced Leadership: The management team has a proven track record in biotechnology and pharmaceuticals.

Risks

  • Financial Uncertainty: As a clinical-stage company, Zymeworks is not yet profitable and relies on external funding.
  • Regulatory and Clinical Risks: The success of its pipeline is contingent on regulatory approvals and clinical trial outcomes.
  • Market Competition: Intense competition could impact the commercial success of its products.

Conclusion

Zymeworks Inc. is a pioneering biotechnology company with a strong focus on developing innovative therapies for cancer and other serious diseases. Its proprietary platforms, robust pipeline, and strategic partnerships position it as a leader in the field of multifunctional biotherapeutics. While the company faces challenges typical of clinical-stage biotech firms, its commitment to innovation and strategic growth provides a solid foundation for future success. Investors should weigh the potential rewards against the inherent risks when considering Zymeworks as an investment opportunity.